Publications by the researcher in collaboration with H. Arasanz Esteban (14)

2024

  1. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

    EMBO Molecular Medicine, Vol. 16, Núm. 8, pp. 1791-1816

2022

  1. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 16

  2. Clinical landscape of LAG-3-targeted therapy

    Immuno-Oncology and Technology, Vol. 14

  3. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

    British Journal of Cancer, Vol. 126, Núm. 8, pp. 1168-1177

2021

  1. A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets

    Journal of Personalized Medicine, Vol. 11, Núm. 6

  2. Understanding lag-3 signaling

    International Journal of Molecular Sciences, Vol. 22, Núm. 10

2020

  1. PD-L1 in systemic immunity: Unraveling its contribution to PD-1/PD-L1 blockade immunotherapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 16, pp. 1-17

  2. Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies

    International Journal of Molecular Sciences, Vol. 21, Núm. 7

2019

  1. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy

    EMBO Molecular Medicine, Vol. 11, Núm. 7

  2. PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer

    International Journal of Molecular Sciences, Vol. 20, Núm. 7

2018

  1. Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography

    Journal of Proteome Research, Vol. 17, Núm. 3, pp. 1172-1182

  2. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives

    Archivum Immunologiae et Therapiae Experimentalis, Vol. 66, Núm. 2, pp. 113-123

2017

  1. PD-L1 signal transduction mechanisms in cancer cells

    Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, Vol. 17, Núm. 2, pp. 72-86

  2. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

    Cell Reports, Vol. 20, Núm. 8, pp. 1818-1829